Scandion Oncology (Scandion), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options, announce the topline results from the second part of the ongoing CORIST phase II trial studying Scandion’s lead compound SCO-101 as a combination treatment with FOLFIRI chemotherapy in patients with metastatic colorectal cancer (mCRC).
The results confirm the safety and tolerability of SCO-101 in this indication and combination. Further, tumor reduction has been observed in some patients, however below the +30% threshold defined as the trial’s primary endpoint. Also, evidence of prolonged progression free survival and stable disease (secondary endpoints) were observed in this hard-to-treat refractory patient population.
Importantly, the data is obtained from the 25 patients enrolled in CORIST part 2, more of whom have only been evaluated after eight weeks of treatment. Patients are still participating in the study, which means that the topline results are not final and could change with longer treatment.
“While we do not achieve a clinical proof of concept for efficacy through these topline results, we are encouraged by the signals observed in the trial, confirming the rationale for combining SCO-101 and FOLFIRI in this indication. We look forward to continuing the development by progressing the CORIST trial further as planned,” says Johnny Stilou, acting CEO of Scandion.
Scandion will continue the CORIST trial enrolling up to 36 patients to be treated according to an optimized dosing schedule as part 3 of the trial. Based on an improved understanding of the pharmacokinetics of SCO-101 in combination with FOLFIRI, increased doses of SCO-101 and chemotherapy will be explored aiming to exploit the full potential of SCO-101 in this indication and combination. The first patient is expected to be enrolled in CORIST part 3 shortly.
Depending on the dose escalation results, CORIST part 3 may be completed by Q3 2023, with an update on the timeline expected in Q1 2023. Scandion then expects to conduct part 4 of the trial, which will conclude the combined CORIST trial.
Webcast and conference call on October 4 at 10:00 am CET
On October 4 at 10:00 am, Scandion Oncology’s executive management will host a webcast and conference call about the topline results from the second part of CORIST.
The event can be accessed via www.scandiononcology.com or through dial in on below numbers:
DK: +45 7876 8490, SE: +46-4-0682-0620, UK: +44 203-7696819, US: +1 646-787-0157
For further information please contact:
Mads Kronborg, Head of External Communication
Phone: +45 6051 4955
This information is information that Scandion Oncology A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on September 30, 2022, at 10.30 CET.
Scandion Oncology (Scandion), the Cancer Drug Resistance Company, discovers and develops first-in-class medicines aimed at treating cancer which is resistant to current treatment options. We are at the forefront of this field, developing novel medicines that address cancer’s resistance against treatment. Our aim is to make existing cancer treatments work better and longer, thereby potentially prolonging and improving the life of patients who would otherwise have a high risk of dying from their cancer.
Globally, close to 10 million patients die every year from cancer and approximately 90 percent of all cancer related deaths are related to cancer drug resistance. Our medicines could be relevant in several cancers and makes both our medical and commercial potential significant.
Scandion is based in Copenhagen and its lead candidate, SCO-101, is currently being studied in clinical phase I and II trials. The company is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL).
Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at email@example.com or +46 (0) 40 200 250.